The iconic rise of Viagra has consistently remained a benchmark of pharmaceutical success, however its position within the broader sector now raises questions about long-term gains. Alternative versions are diminishing market share, leading to anxieties that supporting companies closely tied to Viagra's previous position could be a problematic deci